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Abstract A critical analysis of the literature of mitochondrial
disorders reveals that genetic diseases of oxidative phosphoryla-
tion are often associated with impaired L-oxidation, and vice
versa, and preferentially affect brain, retina, heart and skeletal
muscle, tissues which depend on docosahexaenoic (22:6n-3)-
containing phospholipids for functionality. Evidence suggests
that an increased NADH/NAD ratio generated by reduced flux
through the respiratory chain inhibits L-oxidation, producing
secondary carnitine deficiency while increasing reactive oxygen
species and depleting K-tocopherol (K-TOC). These events result
in impairment of the recently elucidated mitochondrial pathway
for synthesis of 22:6n-3-containing phospholipids, since carnitine
and K-TOC are involved in their biosynthesis. Therapeutic
supplementation with 22:6n-3 and K-TOC is suggested.
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1. Introduction
Disorders of oxidative phosphorylation and L-oxidation are
known to preferentially a¡ect excitatory tissues such as brain,
retina, heart and skeletal muscle [1^3]. These ¢ndings cannot
be explained by depletion of ATP since recent data show that
ATP homeostasis is not signi¢cantly altered in mitochondrial
myopathies [4] ; therefore, impairment of other mitochondrial
functions is likely to be responsible for the preferential path-
ophysiology of excitatory systems. A common denominator
for the nervous and muscular systems is their high content
of docosahexaenoic (22:6n-3)-containing phospholipids [5,6].
A variety of data indicate that these phospholipid species act
as speci¢c structural or conformational cofactors in the func-
tional assembly and integration into organelle membranes of
enzymes, ion pumps (such as the SR Ca2-ATPase) and re-
ceptor proteins, which are particularly active in excitatory
tissues [5,7]. In addition, mitochondria, where the oxidative
phosphorylation machinery is located (recently reviewed in
[8]), have a substantial concentration of 22:6n-3-containing
phospholipids [9,10], suggesting that these are essential for
the functional assembly of the respiratory chain complexes.
Recent evidence suggests that 22:6n-3 is synthesized in mito-
chondria via a carnitine- and K-tocopherol (K-TOC)-depen-
dent enzymatic pathway [11] (see Fig. 1). Since mitochondrial
disorders induce secondary carnitine de¢ciency [12,13], and
also lead to depletion of K-TOC [14] due to an increase in
reactive oxygen species (ROS) [1], one would predict impaired
synthesis of 22:6n-3 in these diseases, which should subse-
quently impair functioning of tissues dependent upon phos-
pholipid species containing this fatty acid. Reviewed below
are data indicating that diseases of oxidative phosphorylation
produce impairment in mitochondrial L-oxidation, and vice
versa, and that these disorders result in impaired 22:6n-3 syn-
thesis as a consequence of secondary carnitine and K-TOC
de¢ciency.
2. Mitochondrial pathways of fatty acid desaturation^
elongation
As recently reviewed [7,11,15], there are two independent
desaturation^elongation pathways: a channeled carnitine-
and K-TOC-dependent mitochondrial fatty acid desatura-
tion^elongation system which synthesizes 22:6n-3 (and
22:5n-6) by n-3- and n-6-speci¢c multifunctional enzymes or
enzyme complexes (Fig. 1), and the open microsomal system
which operates via separate desaturases and elongation en-
zymes and is able to synthesize only up to 22:5n-3 (as well
as being able to synthesize 22:5n-6). We have previously dis-
cussed evidence indicating that impaired mitochondrial syn-
thesis of 22:6n-3 can be compensated for by up-regulation of
the microsomal synthesis of 22:5n-3 and 22:5n-6 [5,11]. The
net result of the interplay of the mitochondrial and micro-
somal systems is decreased 22:6n-3 and increased 22:5n-3,
thus showing an apparent impairment of v4 desaturation of
22:5n-3. The existence of these two systems explains the fact
that microsomes appear to be devoid of v4-desaturase for n-3
fatty acids even though intact cells can synthesize 22:6n-3 [15].
The involvement of the mitochondrial and microsomal fatty
acid desaturation^elongation systems in mitochondrial disor-
ders is explored below.
3. Disorders of oxidative phosphorylation
Defects in the oxidative phosphorylation machinery mani-
fest clinically by hypotonia, hypoglycemia, non-ketotic lactic
acidosis, myopathy, cardiomyopathy, retinopathy and enceph-
alopathy [1^3]. Histologically, these disorders produce fatty
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in¢ltration of liver and skeletal muscle, and subsarcolemmal
proliferation of abnormal mitochondria (ragged-red ¢bers) [1^
3]. Biochemically, defects of the respiratory chain or of the
adenine nucleotide translocator (ANT) are known to result in
an increased NADH/NAD ratio [16] which inhibits the
Krebs cycle and pyruvate dehydrogenase [17] ; the accumu-
lated pyruvate is reduced to lactate, leading to lactic acidosis.
An increased NADH/NAD ratio inhibits L-oxidation at the
level of the 3-hydroxyacyl-CoA dehydrogenases; defects
downstream of complexes I and II will also inhibit L-oxida-
tion due to decreased electron transfer from the acyl-CoA
dehydrogenases to ubiquinone (which occurs via electron
transfer £avoprotein (ETF) and ETF:ubiquinone oxidoreduc-
tase) [18^20]. One consequence of impaired L-oxidation is the
accumulation of acyl-CoA L-oxidation intermediates, which
are released from mitochondria as carnitine esters (in an at-
tempt to regenerate free CoASH), subsequently transported to
the plasma and ¢nally excreted in the urine; these metabolic
changes result in secondary carnitine de¢ciency [12,13,19]. In-
deed, a number of patients harboring oxidative phosphoryla-
tion defects show low levels of free carnitine in muscle and
plasma, and have impaired L-oxidation [20^24]. Carnitine de-
¢ciency would further impair L-oxidation, leading to a vicious
cycle. Increased NADH/NAD ratios would also be expected
to inhibit carnitine synthesis, since the Q-trimethylaminobutyr-
aldehyde dehydrogenase step in this pathway is catalyzed by
an NAD-driven reaction [13]. In addition, generalized mito-
chondrial cytopathy may further impair carnitine synthesis at
the mitochondrial O-N-trimethyllysine hydroxylase step.
A second consequence of impaired oxidative phosphory-
lation is depletion of K-TOC, due to increased ROS generated
through accumulation of free radical intermediates [1,14].
Therefore, defects in the oxidative phosphorylation machinery
are predicted to result in impaired carnitine- and K-TOC-de-
pendent 22:6n-3 synthesis. If 22:6n-3-containing phospholip-
ids are required for assembly of the respiratory chain com-
plexes and operation of the SR Ca2-ATPase pump [5],
depletion of these phospholipid species would further impair
oxidative phosphorylation and muscle contractility, and could
account for the hypotonia and myopathy observed in these
diseases. Consistent with this contention is the fact that vita-
min E de¢ciency impairs 22:6n-3 synthesis [11], leads to de-
creased activity of some of the respiratory chain complexes
[25] and produces myopathy in man and experimental animals
[26,27]. Low levels of red blood cell K-TOC have been found
in a number of mitochondrial defects [14]. Supplemental K-
TOC given to a patient with decreased ANT resulted in a
surprising therapeutic response: the patient went from being
wheelchair-bound to being able to walk and play unassisted
[28]. The increased oxidative stress in ANT is likely to lead to
reduced levels of K-TOC; supplementation with K-TOC might
have restored the synthesis of 22:6n-3-containing phospholip-
ids. If the electron transport complexes were more tightly
coupled as a result of an increased supply of 22:6n-3-contain-
ing phospholipids, this could have improved the residual ANT
activity and decreased ROS production. Consistent with the
role of these phospholipids in electron transport coupling and
decreased ROS is the observation that 22:6n-3 supplementa-
tion to aged rats decreased ROS levels in the brain [29].
4. Diseases of impaired L-oxidation
Defects in the mitochondrial fatty acid L-oxidation machi-
nery have recently been reviewed [30^32]. The clinical mani-
festations of these diseases bear a great similarity to those of
disorders of oxidative phosphorylation. Clinically, they are
characterized by myopathy, cardiomyopathy, pigmentary ret-
inopathy and tissue steatosis, with fasting producing non-ke-
totic lactic acid acidosis and hypoglycemia [12,13,30^34] ; the
neonatal forms also manifest hypotonia [3,31]. Histologically,
they induce proliferation of aberrant mitochondria [35]; bio-
chemically, they produce a striking elevation of tissue and
plasma carnitine esters in an e¡ort to regenerate free CoASH
from the accumulated acyl-CoAs, with a concomitant de-
crease in free carnitine [2,3,12,13]. Lower levels of free carni-
tine would be expected to impair the carnitine-dependent mi-
Fig. 1. Enzymatic mechanism for the proposed mitochondrial carnitine- and K-tocopherolquinone (K-TQ)-dependent channeled synthesis of
22:6n-3-containing phospholipids with phosphatidylcholine (PC) as an example. The reaction starts with 18:3n-3-carnitine which is transported
across the outer mitochondrial membrane followed by binding of 18:3n-3 to the multifunctional enzyme or enzyme complex (E). A series of en-
zyme-bound alternating desaturations and elongations follows. Each of the three desaturation steps (v6, v5 and v4 n-3 desaturases) requires
two molecules of the K-TOC metabolite K-TQ as an electron withdrawing cofactor (along with one molecule of NADH, which has been omit-
ted from the ¢gure for clarity, to allow for full reduction of the two K-TQ), which results in the formation of two reduced K-tocopherolhydro-
quinones (K-TQH2) which eventually transfer their four hydrogens to molecular oxygen forming two molecules of water; for further details on
the mechanism of K-TQ involvement in polyunsaturated fatty acid desaturation, see [11]. An intramitochondrial source of acetyl units, such as
acetyl-carnitine, is the acetyl donor for the elongation reactions (discussed in [11]). The ¢nal synthesis of 22:6n-3-containing phospholipids re-
quires the transfer of this fatty acid to a glycerophosphodiester acceptor, such as GPC, along with acylation by a second acyl moiety; these
two acylations could either be concerted or occur consecutively via a lyso-PC intermediate (see [59] for details of glycerophosphodiester involve-
ment in phospholipid synthesis).
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tochondrial 22:6n-3 synthesis. Signi¢cantly, recent reports in-
dicate that defects in long chain 3-hydroxyacyl-CoA dehydro-
genase, which induce secondary carnitine de¢ciency, are in-
deed associated with low levels of plasma 22:6n-3, and
supplementation with this fatty acid greatly improves the clin-
ical condition [36^38]. Interestingly, this decrease in 22:6n-3 is
accompanied by normal concentrations of 22:5n-3 [37], which
is consistent with a compensatory up-regulation of the micro-
somal desaturation^elongation pathway. We would also pre-
dict increased microsomal synthesis of 22:5n-6, as has been
observed in other disorders associated with impaired 22:6n-3
synthesis [7,11].
As discussed above, decreased 22:6n-3 synthesis induced by
de¢ciency of free carnitine may impair the functional assem-
bly of the respiratory chain complexes of oxidative phosphor-
ylation, in addition to decreasing SR Ca2-ATPase activity.
Indeed, L-oxidation defects are associated with impaired oxi-
dative phosphorylation [24,39]. The accumulation of acyl-
CoAs and/or acylcarnitines could also inhibit oxidative phos-
phorylation and desaturases via the known surfactant e¡ects
of these metabolites on membrane-bound enzymes [39] ; acyl-
CoAs are also strong inhibitors of the ANT [40] which can
lead to impaired oxidative phosphorylation.
5. Other conditions associated with decreased carnitine and
22:6n-3 levels
Neuronal ceroid lipofuscinosis (NCL, Batten disease), a se-
vere neurodegenerative disorder, was long thought to be a
disease of increased lipid peroxidation; however, since ROS
metabolizing enzymes show near-normal activities [41] and
blood levels of K-TOC are actually increased in NCL [42],
this is not the case. Recent evidence convincingly shows that
an impairment of the carnitine synthesis pathway at the step
of lysosomal proteolysis of a mitochondrial trimethyllysine-
containing protein is the primary biochemical lesion in this
disease [43]. Since NCL patients show both carnitine de¢-
ciency and abnormally low levels of 22:6n-3, and higher levels
of 20:4n-6 [43^46], an impairment of the carnitine-dependent
pathway of 22:6n-3 synthesis appears to be a major cause of
its pathophysiology; this is consistent with data showing that
supplementation with 22:6n-3 ameliorates its pathology
[47,48]. Other conditions associated with carnitine de¢ciency,
such as treatment with certain pharmacologic agents, vegan
diets, and excess dietary fat intake, also show decreased levels
of 22:6n-3 (but normal 22:5n-3 levels) and higher levels of
20:4n-6 and 22:5n-6 (when measured) [7,13,49^54]. These ob-
servations indicate an impairment of the carnitine-dependent
pathway of 22:6n-3 synthesis and compensatory up-regulation
of the microsomal desaturases. In the absence of 18:3n-3 de-
¢ciency, a decreased ratio of 22:6n-3/22:5n-6 would be a use-
ful diagnostic index of impaired K-TOC- and carnitine-depen-
dent mitochondrial synthesis of 22:6n-3 in various disorders
or physiological conditions.
6. Proposed therapies for disorders of 22:6n-3 synthesis
Dietary supplementation with appropriate levels of 22:6n-3,
i.e. 10^15 mg/kg body wt/day [55], should be included in the
treatment of disorders of oxidative phosphorylation and L-
oxidation. However, since these conditions also encompass a
more generalized mitochondrial pathology, and the synthesis
of 22:6n-3-containing phospholipids probably requires the
concomitant synthesis of its glycerophosphodiester acyl-ac-
ceptors such as glycerophosphorylcholine (GPC) and glycer-
ophosphorylethanolamine (GPE), which are also synthesized
in mitochondria [56,57], supplementation with commercial
soybean lecithin (5.2^7.8 g, equivalent to 250^375 mg cho-
line/day as required for children [58]) as a source of GPC,
GPE and other glycerophosphodiesters would be advisable
to tap into the extramitochondrial glycerophosphodiester re-
cycling pathways [59], since dietary phospholipids are readily
hydrolyzed to their glycerophosphodiesters by intestinal phos-
pho- and lysophospholipases [60,61]. Alternatively, supple-
mentation with 22:6n-3-containing phospholipids, such as
from 22:6n-3-rich algal lecithin [62] or ¢sh oil lecithin, would
provide both the needed 22:6n-3 and glycerophosphodiesters;
22:6n-3 from algal lecithin is more readily incorporated into
cell phospholipids than it is from triglycerides [62]. Supple-
mentation with 22:6n-3 has already proven bene¢cial in im-
proving retinal and muscle function in other disorders char-
acterized by retinopathy and hypotonia and decreased 22:6n-3
levels, such as Zellweger syndrome and neonatal adrenoleu-
kodystrophy [63,64]. In addition, in diseases of long chain
fatty acid L-oxidation, supplementation with medium chain
triglycerides (which is part of the conventional dietary treat-
ment) should be decreased since dicarboxylic aciduria remains
high when these triglycerides are included at relatively high
levels [65]; dicarboxylic fatty acids are produced by micro-
somal^peroxisomal g-oxidation of excess monocarboxylic
fatty acids. This is not surprising since, contrary to the con-
ventional opinion, recent evidence suggests that exogenous
medium chain fatty acids enter mitochondria as carnitine es-
ters [66,67], and thus would be poorly L-oxidized in the face
of carnitine de¢ciency. Supplementation with carnitine (100^
150 mg/kg body wt/day) may also be bene¢cial [13,68]. The
known anti-arrhythmic e¡ects of 22:6n-3 [69] may counteract
the possible arrhythmic e¡ects of excess acylcarnitines.
For mothers who are known heterozygotes for mitochon-
drial disorders, prenatal supplementation with the above nu-
trients is also indicated. Although the mother transfers 22:6n-
3 to the fetus via the placenta [70,71], neonatal hypotonia is
often present in homozygous o¡spring [3,31]; if this hypoto-
nia is due to low levels of muscle 22:6n-3-containing phos-
pholipids, transfer of 22:6n-3 is either inadequate or is not
being incorporated into the proper muscle acyl-speci¢c phos-
pholipids. This would be the case if these fetuses have a con-
comitant defect in GPC and GPE synthesis, which also occurs
in mitochondria [56,57] ; this would not be surprising since
generalized mitochondrial cytopathy has been described in
these diseases [1,35]. A similar prenatal supplementation
might also be bene¢cial in other diseases which involve mito-
chondrial cytopathy such as Zellweger syndrome [72], as these
patients are known to have both low levels of 22:6n-3 and
hypotonia at birth [73] ; supplementation with 22:6n-3 re-
solves this condition [63].
7. Experimental animal models
There are three experimental animal models which would
be useful to test the proposed mechanisms of impaired 22:6n-
3 synthesis by defects in oxidative phosphorylation, mitochon-
drial L-oxidation and carnitine de¢ciency, as well as the e¡ects
of the above proposed dietary modi¢cations. The knock-out
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mouse (Ant1PGKneo3=3) for the heart/muscle isoform of the
ANT (ANT1), which uses the electrochemical gradient across
the inner mitochondrial membrane to drive the exchange of
ATP for ADP, is a valuable model for mutations in oxidative
phosphorylation, since defects in this translocator will inhibit
the electron £ux in the respiratory chain and ATP synthesis
[16]. These mice develop the expected myopathy with ragged-
red ¢bers (i.e. subsarcolemmal accumulations of abnormal
mitochondria) and cardiomyopathy [16]. Although carnitine
levels in these mice have not been determined, in one human
case with a 4-fold decrease in the muscle-speci¢c ANT, lower
levels of total carnitine were reported in muscle [74], which is
consistent with secondary impairment of L-oxidation; un-
fortunately, levels of free carnitine and 22:6n-3 were not de-
termined. This mouse model also displays increased oxidative
stress [16], suggesting that it has lower levels of K-TOC. The
Ant1PGKneo3=3 mouse would be a valuable tool to determine
if defective ANT1 produces the expected decreases in free
carnitine, K-TOC and 22:6n-3, and impaired L-oxidation.
A second model of interest is the knock-out mouse for long
chain acyl-CoA dehydrogenase (LCAD) which reproduces
much of the pathophysiology of the human disease having
the same enzymatic defect [75], and would also be a good
model for other mitochondrial disorders of L-oxidation such
as of the long chain 3-hydroxyacyl dehydrogenase. The
LCAD(3/3) genotype shows the expected increased levels
of acylcarnitines [75] ; however, the free carnitine status of
these mice was not reported. We would predict a decrease
in free carnitine and a resultant impaired synthesis of 22:6n-
3 accompanied by compensatory increases of 22:5n-3 and
22:5n-6. This LCAD-de¢cient mouse would be a valuable
tool to test the prediction that defects in L-oxidation lead to
impaired oxidative phosphorylation via the mechanisms dis-
cussed above.
The two knock-out mouse genotypes for NCL, which have
recently been produced by targeted disruption of the mouse
ortholog of the CLN3 gene (CLn3) [76,77], provide a third
valuable model to study the role of carnitine in 22:6n-3 syn-
thesis ; these mice would be expected to have impaired syn-
thesis of carnitine and 22:6n-3.
The three mouse models above would constitute valuable
tools for determining the e¡ects of dietary and prenatal sup-
plementation with carnitine, K-TOC, 22:6n-3 (at levels that do
not produce peroxisomal proliferation, i.e. 0.2% of diet by
weight [55]) and lecithin (3.3% of diet by weight, equivalent
to 0.16% dietary choline [78]) on the pathophysiology of these
diseases. However, for these experiments, it would be essential
to provide controls with de¢ned diets without pre-formed
22:6n-3, but with adequate 18:3n-3 and 18:2n-6, i.e. 1% and
5% of calories, respectively [79]. Most standard laboratory
diets for rodents contain signi¢cant amounts of 22:6n-3
from the ¢sh meal component and this may signi¢cantly con-
tribute to the milder pathophysiology observed in mouse
models for mitochondrial diseases and NCL, in addition to
the capacity of mice to up-regulate microsomal synthesis of
22:5n-3 and 22:5n-6.
8. Conclusion
A variety of apparently unrelated disorders share common
pathophysiological features; these include diseases of oxida-
tive phosphorylation and L-oxidation, in addition to NCL,
Zellweger syndrome, experimental vitamin E de¢ciency, and
carnitine de¢ciency syndromes. Several of these disorders are
associated with decreased levels of 22:6n-3, and this fatty acid
has been used with therapeutic success in three of the above
diseases. A common impairment of the carnitine- and K-TOC-
dependent mitochondrial pathway of 22:6n-3 synthesis would
explain some of the similarities, as each disorder shows low
levels of either carnitine or K-TOC, or has mitochondrial de-
fects.
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